Skip to content
The Kids Research Institute Australia logo

Modelling the impact of long-acting monoclonal antibody, maternal vaccine and hybrid programs of RSV immunisation in temperate Western Australia

Two RSV immunisations products: a maternal vaccine, Abrysvo, and a long-acting monoclonal antibody, nirsevimab, both designed to prevent RSV illness in infants, have recently become available. Modelling evidence is required to inform how to optimally use these products in immunisation programs to reduce the burden of RSV in young children.

Citation:
Giannini F, Hogan AB, Blyth CC, Glass K, Moore HC. Modelling the impact of long-acting monoclonal antibody, maternal vaccine and hybrid programs of RSV immunisation in temperate Western Australia. Vaccine. 2026;86.

Keywords:
Abrysvo; Compartmental model; Immunisation; Infant; Infectious disease modelling; Maternal vaccine; Mathematical model; Nirsevimab; RSV; Respiratory syncytial virus; Transmission model

Abstract:
Two RSV immunisations products: a maternal vaccine, Abrysvo, and a long-acting monoclonal antibody, nirsevimab, both designed to prevent RSV illness in infants, have recently become available. Modelling evidence is required to inform how to optimally use these products in immunisation programs to reduce the burden of RSV in young children.